BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $408.7 million versus the consensus estimate of $435.89 million.

GUIDANCE:

BioMarin Pharma sees Q4 2021 revenue of $1.82-1.88 billion, versus the consensus of $1.85 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.